Massachusetts Financial Services Co. MA Purchases 60,496 Shares of Prestige Consumer Healthcare Inc. $PBH

Massachusetts Financial Services Co. MA lifted its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 10.2% in the 4th quarter, HoldingsChannel.com reports. The fund owned 650,793 shares of the company’s stock after buying an additional 60,496 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Prestige Consumer Healthcare were worth $40,147,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Azzad Asset Management Inc. ADV grew its stake in Prestige Consumer Healthcare by 8.4% during the fourth quarter. Azzad Asset Management Inc. ADV now owns 12,696 shares of the company’s stock worth $783,000 after purchasing an additional 986 shares during the period. Portside Wealth Group LLC lifted its stake in Prestige Consumer Healthcare by 9.5% in the fourth quarter. Portside Wealth Group LLC now owns 4,703 shares of the company’s stock valued at $290,000 after buying an additional 408 shares during the period. Three Seasons Wealth LLC boosted its holdings in shares of Prestige Consumer Healthcare by 54.1% during the 4th quarter. Three Seasons Wealth LLC now owns 8,573 shares of the company’s stock worth $529,000 after buying an additional 3,011 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of Prestige Consumer Healthcare by 1.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,613,460 shares of the company’s stock worth $98,776,000 after buying an additional 21,085 shares in the last quarter. Finally, Wedge Capital Management L L P NC grew its position in shares of Prestige Consumer Healthcare by 14.6% during the 4th quarter. Wedge Capital Management L L P NC now owns 57,717 shares of the company’s stock worth $3,561,000 after buying an additional 7,370 shares during the period. 99.95% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently weighed in on PBH shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Jefferies Financial Group cut their target price on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research note on Friday, January 30th. Three analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $76.50.

Prestige Consumer Healthcare Stock Down 0.4%

Shares of NYSE:PBH opened at $56.61 on Wednesday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.93 and a current ratio of 3.11. Prestige Consumer Healthcare Inc. has a 52-week low of $51.24 and a 52-week high of $89.37. The business’s 50 day simple moving average is $63.26 and its two-hundred day simple moving average is $62.49. The firm has a market cap of $2.68 billion, a P/E ratio of 14.98, a PEG ratio of 1.70 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The firm had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. During the same period in the previous year, the company earned $1.22 earnings per share. Prestige Consumer Healthcare’s revenue for the quarter was down 2.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. As a group, research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,000 shares of the company’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total transaction of $65,930.00. Following the transaction, the vice president owned 41,048 shares in the company, valued at approximately $2,706,294.64. This represents a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).